Special Discounts Available! See pg. 7 for details
Source Funding. Forge Partnerships. Manage Relationships. October 25-27, 2010 • The Ritz-Carlton, Laguna Niguel, CA www.bionetworkus.com
Don’t Get Lost In The “Cattle Call” Of The Too-Big Industry Events. Spend Quality Time With The Right People At BioNetwork. •
Gain insights from an unmatched speaker faculty and delegate base all eager to network and share knowledge
•
Maximize over 14 hours of networking activities built into the agenda so that you can have meaningful conversations over the course of three days
•
1:1 partnering software makes it easy for you to schedule private meetings with our speakers and delegates before you get to the conference
•
Onsite facebook allows you to put a face to a name while at the conference. That way you can easily pinpoint who you want to speak with, instead of sifting through a sea of nametags
Top Speakers You Will Meet At BioNetwork: Martin Reeves Vice President, Business Development Cephalon Gregg Talbert Managing Director, Mergers and Acquisitions, Corporate Finance and Investment Banking (CFIB) Group Eli Lilly Robert Wills Vice President Alliance Management, Pharmaceuticals Group Johnson & Johnson
Ellen A. Lubman Strategic Transactions Group Bristol-Myers Squibb James Schaeffer Executive Director, Worldwide Licensing and External Research Merck Chris Seaton Senior Vice President, Global Transactions Bayer Healthcare Pharmaceuticals
Robert Bagdorf Vice President, Worldwide Business Development Pfizer Inc. David Donabedian Vice President, Strategic Alliances, US CEEDD GlaxoSmithKline Kimberly Rogers Vice President, Technology Assessment Allergan
PLUS - 2 Full Afternoons Of The Perfect Pitch – Biotech Investment Challenge! In this groundbreaking session, 4 Biotechs will be given the opportunity to present their “perfect pitch” to our audience of potential partners and investors as well as to our panel of experts who will provide them with invaluable feedback to strengthen their pitches.
Sponsors:
Organized by:
REGISTER Call: 1-888-482-6012 or 1-646-200-7530 Fax: 1-646-200-7535 NOW! Email: bionetwork@wbresearch.com Web: www.bionetworkus.com
New And Improved Networking Opportunities
Improved One-To-One Private Partnering Technology!
We make sure that you meet the people you came to see. Onsite Facebook
•
Tired of sifting through a sea of name tags to find the person you want to meet? Upon check-in, the BioNetwork team will be taking photos of all speakers and attendees so that you can easily spot the person you wish to network with.
• •
Onsite Message Board
•
Placed in a central location by the registration area, the onsite message board allows you to leave notes for speakers or attendees that you are looking to connect with while at BioNetwork West.
Schedule Meetings Before You Arrive! These pre-arranged rooms are available to be booked for 30 minute time blocks. 6 weeks out from BioNetwork West 2010, you will receive a password allowing you to schedule One-To-One Private Partnering Rooms online. On our website you will find a list of registered attendees along with their contact details (viewable at their discretion), a brief description of their companies and partnership aspirations and a timetable of available meeting rooms. Upon receiving an accepted invitation from a potential partner, you will be able to schedule a private partnering room. Please contact Sarah Cascone with any questions regarding the one-to-one partnering site at sarah.cascone@wbresearch.com or 646-200-7497.
Conference Day 1 7:45
Networking Breakfast For All Attendees Conference Registration Sponsored By:
8:30
Chairperson’s Opening Remarks
8:45
Panel Session: Assessing The Deal-Making Landscape For 2010 A Reflective Look At The Deals Done This Past Year
11:00
This case study will look at the recent deal between BMS and Allergan for Allergan’s experimental therapy for neuropathic pain. This session will look into the strategic considerations behind the partnership from both BMS and Allergan's perspectives and delve into the steps and timelines of the partnering process, the due diligence experience, and the status of the relationship today. 11:40
Matthew Q. Reber Vice President Cowen Healthcare Royalty Partners Matthew W. Kalnik, PhD Senior Vice President, Strategic Planning and Business Operations Nabi Biopharmaceuticals
Panel Session: Industry Outlook - What Will The Pharma Space Look Like In 5 Years?
Henry Skinner, PhD Managing Director Novartis Venture Funds
Chris Seaton Senior Vice President, Global Transactions Bayer HealthCare Pharmaceuticals
With limited opportunities in IPO and traditional forms of funding dried up, the market has had to employ creative methods of financing. This session will look at the new financing models currently being used in the pharmaceutical industry: Corporate alliances, grants and government contracts; Monetizing assets in your portfolio to raise capital; Assessing international licensing options; Utilizing partnering as a means to gain capital.
Robert Bagdorf Vice President, Worldwide Business Development Pfizer Inc. Executive Speaker and Panel Moderator Campbell Alliance
2
Refreshment Break And Networking Opportunity
Panel Session: Securing Funding In A Dry Market - The Industry Has Changed, Have You? Mark Benedyk Head The Pfizer Incubator LLC
Much has happened in the pharmaceutical space in the past year. Now is the perfect time to get a read on how the industry fared in 2010. This opening panel session will analyze important developments in 2010 and its impact on the industry on a larger scale: Outlining major deals in 2010; evaluating financing in 2010; updates on the IPO window; Increase in foreign companies buying into the US market and who’s partnering with whom?
10:15
Case Study: BMS And Allergan Global Agreement For Investigational Neuropathic Pain Medicine
Kimberly Rogers Vice President Technology Assessment Allergan
John Hebert Associate Director, Corporate Development Genzyme
In the wake of healthcare reform, the economic recession, industry consolidation and the patent cliff the pharmaceutical space has seen considerable changes that will only continue. This session will look at the pharmaceutical industry outlook and provide predictions for what we can expect in the coming years: impact of the healthcare reform on R&D and BD; effects of industry consolidation; how will big Pharma offset the negative impact of dwindling pipelines.
*To view Who You Are Going To Meet At BioNetwork, please visit the website www.bionetworkus.com.
Tim Herpin Director, Search and Evaluation, Strategy, Alliances and Transactions Bristol-Myers Squibb
Jim Hattersley Vice President Corporate Business Development Sun Pharmaceutical Industries, Inc.
9:30
You have the opportunity to reserve the One-To-One Private Partnering Rooms for all three days of BioNetwork West where you can privately discuss the specifics of your companies, your goals, and your compounds.
Monday, October 25, 2010
Martin Reeves Vice President Business Development Cephalon
Paul Darling Principal ZS Associates
Internal messaging capability Scheduling blocking function Personalized meeting requests designed to avoid spam filters Conference agenda accessible through partnering software
12:25
Networking Lunch For All Conference Attendees Sponsored by:
1:35
Case Study Part 2: Merck/Schering Plough Merger James Schaeffer Executive Director, Worldwide Licensing and External Research Merck Following up on the case study delivered at the BioNetwork East conference in March 2010, Dr. Jim Schaeffer joins us at BioNetwork West to continue the story of the merger of two giants in the industry – Merck and Schering Plough. Jim will share the process used during the integration and will share significant
Call: 1-888-482-6012 or 1-646-200-7530 Fax: 1-646-200-7535 Email: bionetwork@wbresearch.com Web: www.bionetworkus.com
progress of the New Merck, the resulting pipeline, current partnership interests, and finally, the next steps for the New Merck and your partner of choice. 2:15
The panelists will then have a chance to confer and choose “the perfect pitch” which will be presented at the awards ceremony cocktail reception immediately following the afternoon’s presentations.
IP/Regulatory Update – The Pathway For BioSimilars
Panel of Experts David Donabedian Vice President, Strategic Alliances, US CEEDD GlaxoSmithKline
Len Smith Principal Intellectual Property Counsel Medicis Pharmaceutical Corporation It is no surprise that the healthcare reform bill was passed this spring. What is uncertain, however, is how pieces of this legislation will end up affecting the Pharma space. This session will look at how the new pathway works from the “biosimilars” vs. innovators perspective and how the availability of the pathway might relate to deal making in the future. 2:50
Refreshment Break And Networking Opportunity
3:30
The Perfect Pitch: Biotech Investment Challenge
Fred Aslan Vice President Venrock Kim Kamdar Principal Domain Associates LLC 3:30-3:50 3:50-4:10 4:10-4:30 4:30-4:50 4:50-5:30
Presented by: Thomas Abbott President i3 Pharma Informatics In this groundbreaking session, 4 Biotechs will be given the opportunity to present their “perfect pitch” to our audience of potential partners and investors as well as to our panel of experts.
*For more information on how you can participate in the Biotech Investment Challenge, please contact Mimi Fox at 416-597-4808 or email mimi.fox@wbresearch.com 5:30
Here’s how it works: Each Biotech will give a 20-minute company presentation. Then our panelists, VCs and Investment Banks will give their feedback on the strengths of the pitches just heard, highlighting the portions of the presentations that piqued their interest. This will give the presenting companies, as well as the audience, insight into what sparks the interest of potential partners and investors. This session is a must attend for Pharma, Biotechs, and the investment community.
Conference Day 2
Biotech #1 Presentation Biotech #2 Presentation Biotech #3 Presentation Biotech #4 Presentation Feedback From Our Panel Of Experts
Awards Ceremony And Cocktail Reception For All Attendees Presented by: The “Perfect Pitch” Awards Ceremony and Cocktail Reception will be held directly following this afternoon’s Biotech Investment Challenge. The award, presented by i3 Pharma Informatics and our panel of expert judges, will be given to the best company pitch heard in the afternoon’s session. Join all conference attendees to hear who our panel of experts have chosen as the “Perfect Pitch” for 2010.
Tuesday, October 26, 2010
7:45
Networking Breakfast For All Attendees Conference Registration Sponsored By:
Kris Ford Vice President Business Development Intelliject
8:30
Chairperson’s Opening Remarks
This case study will explore the recent deal between sanofi-aventis and Intelliject from each side's perspective. This session will discuss the motivations behind the partnership and include the following: 1) Brief company overview, 2) Product overview, 3) Deal scope & terms, 4) Strategic considerations that led to the idea, 5) For s-a, why IJ & this deal; for IJ, why s-a & this deal, 6) The process, 7) Update on the status of the relationship today, 8) Lessons learned.
Jeff Totten Vice President Dean & Company 8:45
The Morning After - Ensuring Partnerships Work In The Harsh Reality Of Daylight Robert Wills Vice President Alliance Management, Pharmaceuticals Group Johnson & Johnson
10:25
Refreshment Break And Networking Opportunity
11:10
Hearing From The Little Guy - Spotlight On Small Biotechs Year after year, we hear from Big Pharma on what they look for in potential partners. But partnering is a two-way street. These panel sessions will bring together representatives from biotech companies and Big Pharma companies to offer their insight on the following:
David Donabedian Vice President, Strategic Alliances, US CEEDD GlaxoSmithKline
Part 1- Defining The Difficulties Small Companies Face In Finding A Partner In Big Pharma
Laura Pierce Vice President, Alliance Management Bayer HealthCare Pharmaceuticals
John Mendlein Former CEO Adnexus Therapeutics
Alison Shurell Vice President, Product Marketing Intralinks
Matthew Meyer Vice President Business Development Cerimon
Troy Windt Senior Director, Corporate Development Upsher-Smith Maintaining relationships to work efficiently and effectively over time is paramount in a successful partnership. This session will examine the role of the alliance management function in today’s partnering landscape. • Pinpointing specific examples of the benefits realized through effectively managing your relationships • Measuring the success of an alliance- outlining the metrics to gauge effectiveness • Providing the new team with a secure and neutral platform for information sharing and collaboration to ensure open communication throughout the life of the partnership 9:45
Case Study: Sanofi-Aventis And Intelliject - North American License For A Novel Epinephrine Auto-Injector Thomas Wiatrowski Director, U.S. Business Development Sanofi-Aventis
Sponsors:
This panel session will highlight the problems small Biotechs face when trying to traverse the big Pharma partnering market. Panelists will share their insights on the following: 1) What is the follow up process like for inquiries with big Pharma and how can it be improved?; 2) Outlining the process for finding the appropriate person withi your therapeutic area: How easy is the process? What could be changed? and 3) Highlighting other areas of this process that pose problems for small companies 11:50
Part 2- In A Competitive Bidding Process - What Do Small Companies Look For In A Big Pharma Partner? Katrine Bosley CEO Avila Jason Rhodes Executive Vice President and Chief Business Officer Epizyme Corporation
3
It’s true that in most cases big Pharma has its pick of biotech companies. But in a competitive bidding process, this is not the case. This session will bring together representatives from small Biotechs that have gone through a competitive bid to better understand the following: • Identifying the due diligence process for a small company • What attributes are important in a big Pharma partner? 12:30
Denise McGinn Vice President of Licensing & New Business Development, Pharmaceuticals Group, Johnson & Johnson This case study will discuss the co-promotion of Velcade in Japan from the perspectives of both J&J and Takeda. From the strategic considerations that led to the idea, to the developing evaluations and steps that led to the negotiations, to the due diligence experience, the deal signing and closing, and the status of the relationship today. What was in it for Takeda? For J&J? What “lessons learned” were captured?
Networking Lunch For All Conference Attendees Sponsored By:
1:40
Part 3 - BIG PHARMA Perspective: Defining The Difficulties Small Companies Face In Finding A Partner In Big Pharma
3:00
Refreshment Break And Networking Opportunity
3:30
The Perfect Pitch: Biotech Investment Challenge
Ellen A. Lubman Strategic Transactions Group Bristol-Myers Squibb
In this groundbreaking session, 4 Biotechs will be given the opportunity to present their “perfect pitch” to our audience of potential partners and investors as well as to our panel of experts.
Yael Weiss Director, Licensing & External Research - West Coast Merck Research Laboratories
Panel of Experts Gregg Talbert Managing Director, Mergers and Acquisitions, Corporate Finance and Investment Banking (CFIB) Group, Eli Lilly
Jack Tupman Vice President, Corporate Business Development Eli Lilly and Company
Frank Stokes Managing Director R.W. Baird
Understanding the challenges small biotechs face in gaining the partnership of Big Pharma, it is important to also understand what Big Pharma expects and needs from new partnerships. This panel provides important insights to provide you with a Big Pharma perspective in building and sustaining breakthrough partnerships. 2:20
3:30- 3:50 3:50- 4:10 4:10- 4:30 4:30- 4:50 4:50- 5:30
Case Study: J&J / Takeda Co-Promotion For Velcade In Japan
*For more information on how you can participate in the Biotech Investment Challenge, please contact Mimi Fox at 416-597-4808 or email mimi.fox@wbresearch.com
Kyle D. Kuvalanka Vice President Millenium: The Takeda Oncology Company 5:30
Conference Day 3 7:45
Networking Breakfast For All Attendees Conference Registration Sponsored By:
8:30
Chairperson’s Opening Remarks
9:00
Case Study: Compare And Contrast Two Co-Promotion Deals: Late Stage “Ready To Launch” vs. Early Stage
10:00
Panel Session: Understanding The VC Due Diligence Process When Deciding On Investing In A Company Howard D. Palefsky Managing Director Montreux Equity Partners Fred Aslan Vice President Venrock Kim Kamdar Principal Domain Associates LLC
Roger Graben Senior Vice President, Operations & Business Development Kowa Pharmaceuticals America
For small biotech companies, VC investment is critical to funding R&D projects in their pipeline. With the market for investment as it is, the VC capital is not as free flowing as it once was. Therefore, it is now more critical than ever to have a firm understanding of the due diligence process a VC conducts when evaluating a company.
Blake Salisbury Director Corporate Business Development Eli Lilly and Company 10:45
Refreshment Break And Networking Opportunity
11:30
Case Studies: Assessing The Impact Of The Emerging Markets On The Global Pharmaceutical Space
In December of 2009, Lilly concluded two co-promotion agreements – one with Kowa Pharmaceuticals of America, for a new statin that had already been approved in the US but not yet launched, and another agreement with Incyte Corporation, for an early stage new mechanism oral Rheumatoid Arthritis compound. This case study will include comments/discussion from the senior negotiators from the companies as they compare and contrast the differences in the two deal transaction processes highlighting some of the challenges/ opportunities and solutions associated with the different negotiations.
4
Awards Ceremony And Cocktail Reception For All Attendees
Wednesday, October 27, 2010
Jack Tupman Vice President, Corporate Business Development Eli Lilly and Company
Michael A. Johnson Director Corporate Business Development Eli Lilly and Company
Biotech #1 Presentation Biotech #2 Presentation Biotech #3 Presentation Biotech #4 Presentation Feedback from our panel of experts
Daniel Bagi M.D. Managing Director Riso Pharma Tech Inc. Part 1: Case Study BRIC (11:30-12:15) Part 2: Case Study: MENA (12:15-1:00) It comes as no surprise that the emerging markets will play an integral role in the growth of the pharmaceutical industry. By conservative estimates, the E7 alone will be spending over 100B annually on pharmaceutical products by 2020. This section of the agenda will focus on trends in the emerging markets as well as highlight companies that have successfully capitalized on these growth markets. 1:00
Networking Lunch For All Attendees
2:00
End Of BioNetwork 2010
Call: 1-888-482-6012 or 1-646-200-7530 Fax: 1-646-200-7535 Email: bionetwork@wbresearch.com Web: www.bionetworkus.com
About Our Sponsors Upsher-Smith is constantly looking for strong and trusted partnerships through licensing, joint ventures, profit sharing, codevelopment and co-marketing arrangements. Upsher-Smith has a wide U.S. distribution network, experienced sales force and established customer relationships within all customer segments. Looking to the future, Upsher-Smith is focused on: • Building our current product pipeline • Co-promoting and acquiring women’s health products ready for commercialization • Developing, in-licensing and acquiring CNS products focused primarily on treatments for epilepsy & Parkinson’s disease. Our vision is to become a leader in providing therapies that empower people suffering from central nervous system (CNS) diseases to lead healthy, productive lives. Our focus is simple: Advancing pharmacotherapy. Improving life™. Dean & Company is a strategy consulting firm with a unique mix of both traditional business strategy work and a range of investing activities for large corporations, technology start-ups, and equity funds. We work with senior executives to dramatically improve and sustain their company's performance. Dean & Company has an established, highly successful track record in generating actionable and quantifiable results for our clients in the Life Sciences. These include a number of the largest global companies as well as emerging leaders in the Pharmaceuticals, Biotechnology, and Medical Devices & Technology industries. We additionally have developed specialized expertise in the Vaccines industry. The hallmark of our work in life sciences, as in other industries, is our ability to deliver highly quantitative, analytic-driven solutions to complex business problems and the development of practical, action-oriented recommendations and their associated measurable impact on the bottom-line. Our life sciences capabilities extend across the following industry challenges and issues: Licensing/Strategic Alliances/M&A Due Diligence, Portfolio/Life Cycle Management, Product Commercialization & Launch, Manufacturing & Distribution Strategy, Competitive Intelligence/Benchmarking, Marketing Strategy, Pricing & Reimbursement, R&D Productivity. www.dean.com IntraLinks® provides enterprise-class solutions which facilitate the secure, compliant and auditable exchange of critical information, collaboration and workflow management inside and outside the enterprise. Our on-demand solutions help you organize, manage, share and track information, enabling you to accelerate your workflow, optimize your business processes and realize new profit potential. Since 1997, IntraLinks has been used on critical business processes by more than 750,000 users from 90,000 organizations worldwide, including 10 of the top 10 pharmaceutical companies and hundreds of biotechs. IntraLinks counts 800 of the Fortune 1000 as clients, including enterprises such as AstraZeneca Pharmaceuticals LP, Bank of America, Deutsche Bank and the FDIC. For more information, visit www.intralinks.com. Over 25 years, ZS Associates has helped clients in more than 70 countries measurably improve their results through our comprehensive expertise in sales and marketing consulting, capability building and outsourcing. Our clients include multinational, midsize and entrepreneurial companies around the world, with a deep and long-standing emphasis on the healthcare sector, and the pharma/biotech sector in particular. Through our business development and licensing practice area, we support both large and small pharma/biotech companies with services ranging from strategic portfolio evaluation and business development strategy to evaluation of specific potential partners and deals. ZS has more than 1,300 professionals serving clients from 19 offices worldwide. www.zsassociates.com Sanofi-Aventis, a leading global pharmaceutical company, discovers, develops, and distributes therapeutic solutions to address the world’s expanding healthcare needs. We work to prevent and treat the diseases that we know of today, as well as those we may face tomorrow. With approximately 100,000 dedicated professionals in more than 100 countries, sanofi-aventis is devoted to advancing healthcare around the world. We are committed to maintaining the innovative approach to pharmaceuticals established by our parent company, headquartered in Paris, France. Our U.S. affiliate, with headquarters in Bridgewater, New Jersey, employs approximately 15,000 professionals located throughout the country. Sanofi-aventis, U.S. is a dynamic healthcare organization working to meet the needs of physicians and their patients. At sanofiaventis, each and every day we work for what really matters: health .For more information, visit www.sanofi-aventis.us
Campbell Alliance is the leading management consulting firm specializing in the pharmaceutical and biotechnology industry. The firm's clients include most of the world's top-20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into practice areas, each specializing in a critical industry function: Brand Management, Business Development, Clinical Development, Managed Markets, Sales, and Trade and Distribution. From its locations in Raleigh, NC, Parsippany, NJ, Los Angeles, San Francisco, Chicago, Boston, Philadelphia, New York City, Atlanta, and London, the firm serves clients throughout North America, Europe, and Japan. For more information on Campbell Alliance, please visit http://www.campbellalliance.com EvaluatePharma® is the premier source for commercial analysis in the pharma and biotech sector, delivering exclusive, trusted insight into industry performance. For industry insiders and the investment sector, EvaluatePharma® supports value-enhancing business decisions with unrivalled proprietary insight. EvaluatePharma® sets new industry standards by providing consensus forecasts on global drug sales. Our expertise and innovative approach has driven other pioneering developments including Merge Company tool, Calendar of Events and interactive NPV Analyzer. But it's not just our expertise that sets us apart. The reliability of our data and depth of coverage provide clients with commercial insights simply not available anywhere else. Gerson Lehrman Group (GLG) manages the world’s leading expert network and provides software and services to support a marketplace for expertise. GLG's unparalleled network of leading expert consultants, known as the GLG CouncilsSM, includes more than 175,000 subject matter experts and many key opinion leaders (KOLs) who educate and provide insight to decision makers worldwide. Healthcare companies use GLG to accelerate business development research and gather superior market intelligence. GLG’s expertise reaches every sector of the healthcare industry, from the mid-sized and most specialized organizations to some of the largest pharmaceutical, biotechnology, healthcare services, and medical device and supply companies in the world. Visit us at www.glgroup.com. i3 is a full-service, global contract research company providing clinical research services for biotech and pharmaceutical clients. i3 takes a 360-degree view of health care to help its global pharmaceutical, biotechnology, and medical device clients bring safe and effective products to market quickly and help demonstrate their value, leading to increased ROI and better patient care. i3’s Pharma Informatics combines unparalleled data assets, online tools, and scientific expertise to help you attain a clearer understanding of your products’ potential and corresponding market dynamics—so you can make more rapid, informed decisions throughout development and commercialization. Founded in 1876, Eli Lilly and Company is now the 10th largest pharmaceutical company in the world. Lilly has steadfastly remained independent, but not isolated. Across the globe, Lilly has developed productive alliances and partnerships that advance our capacity to develop innovative medicines at lower costs. Lilly is consistently ranked as one of the best companies in the world to work for, and generations of Lilly employees have sustained a culture that values excellence, integrity, and respect for people. Lilly's global employees number approximately 40,000, and our medicines are marketed in 143 countries. Lilly has major research and development facilities in eight countries and conducts clinical trials in more than 50 countries. Lilly makes medicines that help people live longer, healthier, more active lives. Symphogen is developing superior antibody therapeutics to help people with seri¬ous diseases. With its proprietary Symplex™ discovery and Sympress™ manufacturing platforms, the company captures the diversity and specificity of the natural immune response in rationally designed recombinant antibody composi¬tions. Symphogen is maturing a diversified pipeline of internal and partnered prod¬ucts across multiple indications including cancer and infectious disease. Its technologies and expertise within the antibody field have been validated through corporate partnerships with pharmaceutical companies in the US, Europe, and Japan. Symphogen’s corporate office is located in Lyngby, Denmark and employs 70 people. Symphogen’s US subsidiary, Symphogen, Inc. is headquartered in Princeton, NJ.
SPONSORSHIP OPPORTUNITIES AVAILABLE Don’t miss your chance to be in front of the top pharmaceutical and biotech companies in North America. If you are offering a solution, service, or technology that will help companies improve research and development, search and evaluation, licensing, strategic alliances, due diligence, or simply want to show how you are the partner of choice in fueling opportunities for increasing drug pipelines, contact Jodi Richter, Director of Sponsorship and Sales,
646-200-7485 or email jodi.richter@wbresearch.com.
Sponsors:
5
About Our Media Partners BioPharm Insight provides the most comprehensive information and forward-looking insight to help you easily find the answers you need within the Biotechnology and Pharmaceutical industry. It includes the entire drug discovery and development pipeline, approved drugs, licensing deals, pharmaceutical sales/projections, management contacts and more.
Laboratory Network is the premier Internet source of useful and timely information about the laboratory industry. The site is directed to chemists, researchers, laboratory managers and research directors, as well as users, purchasers and manufacturers of laboratory equipment, chemicals, and supplies. Laboratory Network provides daily news updates and reports on business and technology trends vital to the industry.
BioPharm International integrates the science and business of biopharmaceutical research, development, and manufacturing. We provide practical, peer-reviewed technical solutions to enable biopharmaceutical professionals to perform effectively. BioPharm is the longestrunning peer-reviewed publication serving an international audited audience involved in the development, manufacturing of therapeutics and management of related business issues.
Established in 1965, the Licensing Executives Society (U.S.A. and Canada), Inc. (LES) is a professional society comprised of over 6,000 members engaged in the transfer, use, development, manufacture and marketing of intellectual property. The LES membership includes a wide range of professionals, including business executives, lawyers, licensing consultants, engineers, academicians, scientists and government officials. Many large corporations, professional firms, and universities comprise the Society's membership. Licensing Executives Society (U.S.A. and Canada), Inc. is a member society of the Licensing Executives Society International, Inc. (LESI), with a worldwide membership of over 12,000 members in 30 national societies, representing over 80 countries.
Bioresearch Online is the premier sourcing site for industry professionals. Use our supplier directory, product showcase, and offline search service to expedite your discovery of new products and services. Our goal is to help buyers, like you, identify and select the right suppliers. BioWorld Today, the newspaper of record for the biotechnology industry, is read by thousands of biotechnology professionals worldwide for its hard-hitting, objective news reporting and insightful analysis covering news on public companies and hard-to-find information on private companies. Delivered by e-mail every business morning, we are also found exclusively online at www.BioWorld.com. CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture capital directories and databases. Publications include the Bio Outsourcing Asia© Publication. www.canbiotech.com CurrentPartnering is an online provider of best practice, business information and intelligence for dealmakers. The core of our service is to provide access to latest best practice, business intelligence and information for dealmakers. We search out the latest information so you don’t have to and place it in one location, saving you precious time and resources. CurrentPartnering is a publisher in its own right, publishing a series of reports each year and providing access to critical decision making and best practice intelligence from leaders in the partnering field. Our most recent report titles include: • Option & Evaluation Agreements in Pharma & Biotech • Royalty Financing Terms and Agreements in Pharma, Biotech & Diagnostics, 2nd Edition • Practical Guide to Finding Partners in Pharma & Biotech, 3rd Edition • Clinical Stage Partnering Terms and Agreements in Pharma & Biotech, 2nd Edition For more information about us, please visit www.currentpartnering.com Cutting Edge Information delivers an innovative approach to comprehensive pharmaceutical and biotechnology benchmarking data. CEI offers objective, proprietary primary and secondary research on critical industry issues. CEI offers customized consulting services and a growing library of targeted and insightful pharmaceutical research reports. Drug Discovery Online covers drug discovery like no other Internet site. Each day we present the most interesting, useful feature stories, case studies, industry news, and newswire feeds related to the science and business of discovering new drugs. Throughout the year Drug Discovery Online presents news and opinions on the latest discovery technology, from organic synthesis and the manual isolation of new compounds from exotic plants, to combinatorial chemistry and high-throughput screening. FierceBiotech is the biotech industry's daily monitor. Senior biotech industry professionals rely on FierceBiotech to stay up to speed on biotech corporations, FDA approvals & regulations, industry mergers & acquisitions, clinical trials, and more through our comprehensive website and free email newsletter. http://www.FierceBiotech.com Georgia Bio (www.gabio.org) is the private, non-profit association representing more than 300 pharmaceutical, biotechnology, medical device and diagnostic companies, healthcare systems, universities, research institutes and other organizations involved in the research and development of life sciences products that improve the health and well-being of people, animals and the environment worldwide.
6
Life Science Leader strives to be an essential business tool for Life Science executives. The editorial is designed to provide readers with content pertaining to the life cycle of Life Science products and services. Our goal is to provide information that helps high-level industry personnel improve profits and overcome hurdles within the industry. For more than 25 years, Med Ad News has provided the busy pharmaceutical executive with need-to-know business information. Each issue delivers broad coverage and penetrating analysis of issues, events, trends, and strategies shaping the pharmaceutical industry. Published monthly, Med Ad News provides exclusive content examining historical trends pertaining to and current events affecting the sales and marketing of medicines and the companies that manufacture them. To learn more about Med Ad News and other products from Canon IMM Inc. visit www.pharmalive.com or call 215-944-9800. Published by Espicom Business Intelligence, Pharma Agreement News is the twice-monthly business publication that concisely reports on hundreds of agreements and deals between phamaceutical companies worldwide. For further information and to order your subscription today, visit www.espicom.com/pan Pharmaceutical Online is the online industry standard for pharmaceutical manufacturing. Use our supplier directory, product showcase, and offline search service to expedite your discovery of new products and services. Our goal is to help buyers, like you, identify and select suppliers. Pharma Connections Worldwide® is the leading professional business networking website focused in the Pharmaceutical, Biotechnology and Life Sciences research industry. Our goal is to provide a conduit for delivery of premiere content coupled with the right clientele in order to facilitate business development opportunities amongindustry professionals responsible for making key decisions in a global marketplace. PharmaVOICE magazine, and its supporting VIEW publications, provide commentary about the challenges and trends impacting the life-sciences industry, covering a range of issues from molecule through market. PharmaVOICE's more than 17,500 U.S.-based subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers. The Scientist, the award-winning magazine of the life sciences, provides compelling print and online coverage of the latest developments in the life sciences including research, technology, and business. We entertain and inform our readers, keeping them up-to-date with latest news, events, culture, innovations and career advice. Visit us at www.the-scientist.com. Updated daily on the web or twice-monthly in print, World Generic Markets distils the important generic market news worldwide. Published by Espicom Business Intelligence, World Generic Markets is fast becoming the publication of choice for drug developers, the pharmaceutical manufacturers, service companies, commerce, investors and regulators - make sure you get the benefits too! For further information and to order your subscription today, visit www.espicom.com/wgm
Call: 1-888-482-6012 or 1-646-200-7530 Fax: 1-646-200-7535 Email: bionetwork@wbresearch.com Web: www.bionetworkus.com
Registration Information The Perfect Pitch: Biotech Investment Challenge
Sponsorship Opportunities Available
In these innovative sessions eight Biotechs will be given the opportunity to present their “perfect pitch” to our audience of potential partners and investors as well as to our panel of experts.
Find out how you can sponsor BioNetwork 2010. Unlike huge industry events, BioNetwork allows you to meet senior executives from different Pharmaceutical and Biotech companies on a one-to-one basis. For sponsorship inquiries please contact: Jodi Richter, Director of Sponsorship and Sales, 646-200-7485 or email jodi.richter@wbresearch.com.
Each Biotech will give a 20 minute company presentation highlighting their current projects. Then our panelists, consisting of big Pharma, VCs and Investment Banks will give their feedback on the strengths of the pitches just heard- highlighting the portions of the presentations that piqued their interest. This will not only give the presenting companies the platform to attract new partners, but will also give the presenting companies, and audience alike, insight into what sparks the interest of potential partners and investors. This session is a must attend for Pharma, Biotechs, and the investment community.
Tell Us Who You Want To Meet At BioNetwork 2010! If you're already registered or are planning to register for BioNetwork 2010, tell us about five people you would like to meet at the event. We will reach out to them on your behalf to get them registered. Once they register, we will notify you, so you can set up one-on-one meetings with them onsite at BioNetwork.
The panelists will then have a chance to confer and choose “the perfect pitch” which will be presented at the awards ceremony cocktail reception immediately following the afternoon’s presentations.
Send your list of names, including job title, company, phone and email address to bionetwork@wbresearch.com or go to our website at www.bionetworkus.com and complete the online form.
If your company is interested in joining one of the Investment Challenge afternoons, contact Mimi Fox at 416-597-4808 or email mimi.fox@wbresearch.com! Spaces are limited so sign up today!
Hotel Information Ritz Carlton Laguna Niguel One Ritz Carlton Drive, Dana Point, CA 92629 Tel. 949-240-2000 Fax. 949-240-0829 http://www.ritzcarlton.com/en/Properties/LagunaNiguel/Default.htm
Conference Pricing Pricing
3 Day Conference
Group Discounts for Teams of 2 or More
3 Day Conference
Register & Pay Register & Pay Register & Pay By 7/30/2010 To By 8/31/2010 To By 9/30/2010 To Get $600 Off Get $400 Off Get $200 Off $2,600
$2,800
$3,000
Register & Pay Register & Pay Register & Pay By 7/30/2010 To By 8/31/2010 To By 9/30/2010 To Get $800 Off Get $600 Off Get $400 Off $2,400
$2,600
$2,800
Experience genuine renewal at The Ritz-Carlton, Laguna Niguel. Situated atop a 150-foot bluff, this peaceful sanctuary soars above the standard Laguna hotels with refined elegance, a graceful atmosphere and impeccable service. Located halfway between Los Angeles and San Diego, the luxury oceanfront resort offers panoramic white-water views of the Pacific. The Ritz-Carlton, Laguna Niguel is a luxury resort like no other.
Full Price $3,200
BioNetwork has procured a special conference rate of $330.00 per night (plus tax). To book your reservations, call the Ritz Carlton Laguna Niguel at 949-240-2000 or 1-800-241-3333 and identify yourself as a BioNetwork attendee. Rooms are limited and are on a first come, first served basis, so make your reservations as soon as possible. The discounted rate expires September 24th, 2010. After September 24th, rooms may still be available, so inquire with the hotel if you have missed the cut off date.
Get $200 Off $3,000
PURCHASE SELECT AUDIO PRESENTATIONS* FROM THIS EVENT!
Airport Options
Can't make it to BioNetwork 2010 or worried that there is too much information to digest in a few short days at the event? No need to worry. You can purchase select audio presentations to share with your entire team.
•
•
Register for the event today and for an additional $250 gain access to select audio presentations from this event. Can’t attend? Purchase the CD-ROM only for $580
•
•
*Presentations available are at the approval of conference speakers. Allow 3-4 weeks after event date for shipping.
Small Biotechs & University Pricing Available!
For every registration received for Bio Network, WBR will donate a portion of the registration fee to Smile Train. For more information about WBR’s involvement with Smile Train, please visit bionetwork@wbresearch.com.
Please inquire about discounted rates at bionetwork@wbresearch.com or contact Mimi Fox at mimi.fox@wbresearch.com, 416-597-4808 to learn more.
Please Note: • To secure your team discount, register online at www.bionetworkus.com or contact Bill Penney at 1-866-691-7771 or bpenney@wbresearch.com • Team discounts must be booked and paid for at the same time. Team discounts do not apply to sponsoring or exhibiting companies or non pharmaceutical, biotech company. • All discounts are taken off the full conference price. No two discounts or offers can be combined. • Payment is due in full at the time of registration. Your registration will not be confirmed until payment is received and may be subject to cancellation • For payment methods and to register now, please visit www.bionetworkus.com.
Sponsors:
John Wayne/Orange County Airport; SNA (25 minutes/23 miles) http://www.ocair.com/ Long Beach Airport; LGB (45 minutes/44 miles) http://www.lgb.org/ Los Angeles International Airport; LAX (60 minutes/63 miles) http://www.lawa.org/ San Diego Lindbergh Field Airport; SAN (75 minutes/67 miles) http://www.portofsandiego.org/
Delegate Substitutions And Cancellations: You may substitute delegates at any time by providing reasonable advance notice to WBR. • For any cancellations received in writing not less than thirty (30) days prior to the conference, you will receive a 75% credit to be used at another WBR conference which must occur within one year from the date of issuance of such credit. An administration fee of 25% of the contract fee will be retained by WBR for all permitted cancellations. • There are no refunds given under any circumstances. •
7
WBR 535 Fifth Avenue, 8th Floor New York, NY 10017 October 25-27, 2010 The Ritz-Carlton, Laguna Niguel, CA www.bionetworkus.com
“BioNetwork is a top tier biotech/pharma industry conference, integrating business development executives with many strong partnering functions - great venues & very productive results” - Jim Hattersly, Vice President, Corporate Business Development, Sun Pharmaceutical Industries, Inc.
Your priority booking code is:
When registering please provide the code above.
Attention Mailroom: If undeliverable to addressee, this time sensitive information should be forwarded to the
VP of Business Development
10386.005/GS
Special Discounts Available!
See pg. 7 for details
Source Funding. Forge Partnerships. Manage Relationships.
October 25-27, 2010 • The Ritz-Carlton, Laguna Niguel, CA • www.bionetworkus.com
“I have always found the BioNetwork meetings very productive. Due to its more intimate setting, it is very easy to meet with companies and share ideas. This setting coupled with a well organized and professionally managed conference always delivers a positive experience.” - Mark Dennish, Vice President, Business Development, Daiichi Sankyo
•
•
23 interactive and educational panel sessions and case studies presented by executive level industry leaders
30+ private one-to-one meeting opportunities
•
•
•
•
•
2 rewarding cocktail receptions
3 networking lunches
3 networking breakfasts
5 networking refreshment breaks
Organized by:
1 essential opportunity to source funding, forge partnerships, and manage relationships with the decision makers in your industry
Don’t Miss These Exclusive Networking Opportunities Unique To BioNetwork:
•
Biotech Research Presentations at the Perfect Pitch: Biotech Investment Challenge
Sponsors:
REGISTER Call: 1-888-482-6012 or 1-646-200-7530 Fax: 1-646-200-7535 NOW! Email: bionetwork@wbresearch.com Web: www.bionetworkus.com
Organized by:
Can’t make it to: or afraid there is too much information to digest in just a few days? Get Access to hours of valuable sessions and take-ways anytime, anywhere... Now you can view this outstanding conference content on your PC or laptop with a CD-ROM that puts you front and center at these informative sessions. You'll hear our expert speakers as they take you through the PowerPoint slides that illustrated their talks.
This Session Content is available for a fraction of the registration price. You can view and listen to the content when you want, where you want and as many times as you want. And if you attend BioNetwork 2010, this Conference CD-ROM set is only $250! (That’s a $580 value!)
This user friendly format allows you to: •
• •
Gain valuable insight from your peers and competitors in various Fortune 500 Industries without leaving the office. Share with your colleagues at work. Stay up to date with the latest strategies, tactics and trends in your industry.
Now you can share what you learnt at BioNetwork 2010, with your colleagues. Don’t leave them in the dark. Purchase the CD ROM today!
VIP Package: $250 (Select any package to attend the event and for an additional $250 get the conference CD ROM*)
CD ROM ONLY: $580 * *Presentations available are at the approval of conference speakers. Not all presentations will be published. Allow 3-4 weeks after event date for shipping.